Aura Biosciences

First pharmacological treatment for ocular melanoma

Aura BioSciences is using its proprietary VDC (virus-like particle-drug conjugates) platform to develop products to treat high unmet needs in ocular and urologic cancers.

Aura’s clinical pipeline includes AU-011, its most advanced product, which is poised to begin registrational studies in primary choroidal melanoma and which is also in Phase I studies in non-invasive muscle bladder cancer.

CEO  Elisabet de los Pinos

Advent Contact  Raj Parekh

Advent invested in the Series B in 2015.
Publicly Listed
1 December 2022 in Aura Biosciences, Press Release, Publicly Listed

Aura Biosciences Announces Pricing of Public Offering of Common Stock

Press Release. BOSTON--(BUSINESS WIRE)-- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced…
Read More
10 November 2022 in Aura Biosciences, Press Release, Publicly Listed

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Press Release. Announced the Global Phase 3 Trial Design with Suprachoroidal Route of Administration of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma First Patient Dosed in the Phase 1 Study Evaluating…
Read More
10 November 2022 in Aura Biosciences, Press Release, Publicly Listed

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Press Release.   BOSTON, MA – November 10, 2022 – Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for…
Read More
3 October 2022 in Aura Biosciences, Press Release, Publicly Listed

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

Press Release.   BOSTON - (BUSINESS WIRE) - Oct. 3, 2022 - Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC)…
Read More